Brain Glucose: The New Frontier in Chinese Alzheimer’s Research 2026
Chinese researchers at the Kunming Institute of Zoology successfully reversed Alzheimer's symptoms in mice by restoring brain glucose levels via the GLUT1 protein.
Could a simple sugar be the missing piece in the Alzheimer’s puzzle? A team from the Kunming Institute of Zoology, under the Chinese Academy of Sciences, has reported a significant breakthrough. By focusing on glucose levels rather than just protein buildup, researchers managed to reverse memory loss in mice with late-stage symptoms.
Targeting GLUT1: Chinese Alzheimer’s Glucose Study Results
According to the study published in Advanced Science on December 8, 2025, the experimental treatment aims to restore the brain's energy supply. The researchers hypothesize that Alzheimer's may stem from an abnormally low supply of glucose, leading to a total collapse of brain energy metabolism.
The drug targets the GLUT1 glucose transport protein. In mice trials, the results were outstanding: memory loss was substantially reversed, and brain plaques were significantly reduced within weeks of treatment. This offers a fresh perspective on a disease that has long frustrated the global medical community.
This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.
Related Articles
Max Hodak's Science Corp raises $230M for rice-grain sized chip that restores vision to blind patients. Could beat Neuralink as first BCI company to commercialize
Trump appointee overruled FDA scientists to reject Moderna's mRNA flu vaccine, then reversed course within a week after public backlash. Political interference in vaccine approval raises concerns.
Artificial intelligence is addressing the talent shortage in drug discovery, offering new hope for thousands of untreated rare diseases through automated research and gene editing.
Harvard professor's biotech startup wins FDA approval for humanity's first age reversal clinical trial using cellular reprogramming technology. Can we actually turn back time?
Max Hodak's Science Corp raises $230M for rice-grain sized chip that restores vision to blind patients. Could beat Neuralink as first BCI company to commercialize
Trump appointee overruled FDA scientists to reject Moderna's mRNA flu vaccine, then reversed course within a week after public backlash. Political interference in vaccine approval raises concerns.
Artificial intelligence is addressing the talent shortage in drug discovery, offering new hope for thousands of untreated rare diseases through automated research and gene editing.
Harvard professor's biotech startup wins FDA approval for humanity's first age reversal clinical trial using cellular reprogramming technology. Can we actually turn back time?
Thoughts
Share your thoughts on this article
Sign in to join the conversation